Human TACI/TNFRSF13B Antibody, R&D Systems™

TACI/TNFRSF13B/CVID

Monoclonal

Unconjugated

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative

CD267, CD267 antigen, CVID, CVID2, FLJ39942, MGC133214, TACIMGC39952, TNFRSF13B, TNFRSF14B, Transmembrane activator and CAML interactor, tumor necrosis factor receptor 13B, tumor necrosis factor receptor superfamily member 13B, tumor necrosis factor receptor superfamily, member 13B

Mouse

Protein A or G purified from hybridoma culture supernatant

RUO

23495

Reconstitute at 0.5 mg/mL in sterile PBS.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.

IgG1

Western Blot, Immunohistochemistry, Blockade of Receptor-ligand Interaction, ELISA

165609

Western Blot 1 ug/mL, Immunohistochemistry 8-25 ug/mL, Blockade of Receptor-ligand Interaction, ELISA Capture (Matched Antibody Pair) 2-8 ug/mL

O14836

TNFRSF13B

Mouse myeloma cell line NS0-derived recombinant human TACI/TNFRSF13B Ser2-Thr166 Accession # O14836

25 μg

Primary

Detects human TACI/TNFRSF13B in ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant mouse TACI or recombinant human BCMA is observed.

Human

Purified